Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours

British Journal of Cancer

Volumn 73, Issue 12, 1996, Pages 1569-1575

  Schellens, J H M ^a   Ma, J ^a   Planting, A S Th ^a   Van Der Burg, M E L ^a   Van Meerten, E ^a   De Boer Dennert, M ^a   Schmitz, P I M ^a   Stoter, G ^a   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Cisplatin; DNA adduct; Pharmacokinetics; Solid tumour

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA ADDUCT; DRUG BLOOD LEVEL; FEMALE; GASTROINTESTINAL TOXICITY; HEAD CANCER; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; LEUKOPENIA; MALE; NECK CANCER; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 0030038773     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.296     Document Type: Article

References (64)

1. ALBERTS DS, GARCIA D AND MASON-LIDDIL N. (1991). Cisplatin in advance cancer of the cervix: an update. Semin. Oncol., 18 suppl. 3, 11-24.
2. BAJORIN DF, SAROSDY MF, PFISTER DG, MAZUMDAR M, MOTZER RJ, SCHER HI, GELLER NL, FAIR WR, HERR H, SOGANI P, SHEINFELD J, RUSSO P, VLAMIS C, CAREY R, VOGELZANG NJ, CRAWFORD ED AND BOSL GJ. (1993). Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumours: a multiinstitutional study. J. Clin. Oncol., 11, 598-606.
3. BLOMMAERT FA, MICHAEL CH, TERHEGGEN PMAB, MUGGIA FM, KORTES V, SCHORNAGEL JH, HART AAM AND DEN ENGELSE L. (1993). Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res., 53, 5669-5675.
4. BRUCKNER HW, WALLACH R, COHEN CJ, DEPPE G, KABAKOW B, RATNER L AND HOLLAND JF. (1981). High-dose platinum for the treatment of refractory ovarian cancer. Gynecol. Oncol., 12, 64-67.
5. CALVERT AH, HARLAND SJ, NEWELL DR, SIDDIK ZH, JONES AC, MCELWAIN TJ, RAJU S, WILTSHAW E, SMITH IE, BAKER JM, PECKHAM MJ AND HARRAP KR. (1982). Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum(II). Cancer Chemother. Pharmacol., 9, 140-147.
6. CALVERT AH, NEWELL DR, GUMBRELL LA, O'REILLY S, BURNELL M, BOXALL FE, SIDDIK ZH, JUDSON IR, GORE ME AND WILTSHAW E. (1989). Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7, 1748-1756.
7. CAVALETTI G, MARZORATI L, BOGLIUN G, COLOMBO N, MARZOLA M, PITTELLI MR AND TREDICI G. (1992). Cisplatin-induced peripheral neurotoxicity is dependent on total dose-intensity and single dose-intensity. Cancer, 69, 203-207.
8. CHILDS WJ, NICHOLLS EJ AND HORWICH A. (1992). The optimization of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis in metastatic nonseminomatous germ cell tumours of the testis. Ann. Oncol., 3, 291-296.
9. DAUGAARD G AND ABILDGAARD U. (1989). Cisplatin nephrotoxicity. A review. Cancer Chemother. Pharmacol., 25, 1-9.
10. EASTMAN A. (1986). Reevaluation of interaction of cis-dichloro(ethylenediammine)-platinum(II) with DNA. Biochemistry, 25, 3912-3915.
11. EASTMAN A AND SCHULTE N. (1988). Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry, 27, 4730-4734.
12. EGORIN MJ, VAN ECHO DA, TIPPING SJ, OLMAN EA, WHITACRE MY. THOMPSON BW AND AISNER J. (1984). Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) in patients with impaired renal function. Cancer Res., 44, 5432-5438.
13. EGORIN MJ, VAN ECHO DA, OLMAN EA, WHITACRE MY, FORREST A AND AISNER J. (1985). Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res., 45, 6502-6506.
14. FICHTINGER-SCHEPMAN AMJ, VAN OOSTEROM AT, LOHMAN PHM AND BERENDS F. (1987). cis-Diamminedichloroplatinum (II)-induced DNA adducts in peripheral leucocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-Diamminedichloroplatinum (II). Cancer Res., 47, 3000-3004.
15. GERRITSEN VAN DER HOOP R, VECHT CHJ, VAN DER BURG MEL, ELDERSON A, BOOGERD W, HEIMANS JJ, VRIES EP, HOUWELINGEN VAN JC, JENNEKENS FHI, GISPEN WH AND NEIJT JP. (1990). Prevention of cisplatin neurotoxicity with an ACTH(4 9) analogue in patients with ovarian cancer. N. Engl. J. Med., 322, 89-94.
16. GILL I, MUGGIA FM, TERHEGGEN PMAB, MICHAEL C, PARKER RJ, KORTES V, GRUNBERG S, CHRISTIAN MC, REED E AND DEN ENGELSE L. (1991). Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leucocyte and buccal cell platinum-DNA adducts. Ann. Oncol., 2, 115-121.
17. GLOVER D, GLICK JH, WEILER C, FOX K AND GUERRY D. (1987). WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J. Clin. Oncol., 5, 574-578.
18. GOLDBERG JM AND LINDBLOM U. (1979). Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation. J. Neurol. Neurosurg. Psychiatry, 42, 793-803.
19. HAINSWORTH JD AND GRECO FA. (1993). Treatment of patients with cancer of an unknown primary site. N. Engl. J. Med., 329, 257-263.
20. HANSEN HH. (1992). Management of small-cell cancer of the lung. Lancet, 339, 846-849.
21. HENGSTLER JG, FUCHS J AND OESCH F. (1992). DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res., 52, 5622-5626.
22. HIMMELSTEIN KJ, PATTON TF, BELT RJ, TAYLOR S, REPTA AJ AND STERNSON LA. (1981). Clinical kinetics of intact cisplatin and some related species. Clin. Pharm. Ther., 29, 658-664.
23. HOSMER DW AND LEMESHOW S. (1980). Goodness-of-fit tests for the multiple logistic regression model. Communications Stat., A9, 1043-1069.
24. HOSMER DW AND LEMESHOW S. (1989). Applied Logistic Regression. Wiley: New York.
25. JODRELL DI, EGORIN MJ, CANETTA RM, LANGENBERG P, GOLDBLOOM EP, BURROUGHS JN, GOODLOW JL, TAN S AND WILTSHAW E. (1992). Relationships between carboplatin exposure and tumour response and toxicity in patients with ovarian cancer. J. Clin. Oncol., 10, 520-528.
26. KAYE SB, LEWIS CR, PAUL J, DUNCAN ID, GORDON HK, KITCHENER HC, CRUICKSHANK DJ, ATKINSON RJ, SOUKOP M, RANKIN EM, CASSIDY J, DAVIS JA, REED NS, CRAWFORD SM, MACLEAN A, SWAPP GA, SARKAR TK, KENNEDY JH AND SYMONDS RP. (1992). Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet, 340, 329-333.
27. KRARUP-HANSEN A AND HANSEN HH (1991). Chemotherapy in malignant mesothelioma: a review. Cancer Chemother. Pharmacol., 28, 319-330.
28. LEVIN L AND HRYNIUK WM. (1987). Dose-intensity analysis of chemotherapy regimens in ovarian carcinoma. J. Clin. Oncol., 5, 756-767.
29. LEVIN L, SIMON R AND HRYNIUK W. (1993). Importance of multiagent chemotherapy regimens in ovarian carcinoma: Dose-intensity analysis. J. Natl Cancer Inst., 85, 1732-1742.
30. LOEHRER PJ AND EINHORN LH. (1984). Diagnosis and treatment. Drugs live years later. Cisplatin. Ann. Intern. Med., 100, 704-713.
31. LOGOTHETIS CJ AND AMATO RJ. (1992). Dose-intensity in germ cell tumours: Lessons learned? J. Natl Cancer Inst., 84, 1686-1687.
32. MA J, VERWEIJ J, PLANTING AST, DE BOER-DENNERT M, INGEN VAN HE, VAN DER BURG MEL, STOTER G AND SCHELLENS JHM. (1995). Current sample handling methods for measurement of platinum-DNA-adducts in leucocytes in man lead to discrepant results in DNA-adduct levels and DNA-repair. Br. J. Cancer, 71, 512-517.
33. MARKMAN M. (1993). The role of platinum dose-intensity in the management of ovarian cancer. J. Cancer Res. Clin. Oncol., 119, 511-512.
34. MOTZER RJ, BOSL GJ, GELLER NL, PENENBERG D, YAGODA A, GOLBEY R, WHITMORE WF, FAIR WR, SOGANI P, HERR H, MORSE M, CAREY RW AND VOGELZANG N. (1988). Advanced seminoma: the role of chemotherapy and adjunctive surgery. Ann. Intern Med., 108, 513-518.
35. MOTZER RJ, REED E, PERERA F, TANG D, SHAMKHANI H, POIRIER MC, TSA W-Y, PARKER RJ AND BOSL GJ. (1994). Platinum-DNA adducts assayed in leucocytes of patients with germ cell tumours measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer, 73, 2843-2852.
36. NATIONAL CANCER INSTITUTE. (1988). Common Toxicity Criteria. Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute: Bethesda, MD.
37. OZOLS RE. (1989). Cisplatin dose-intensity. Semin. Oncol., 16, 22-30.
38. OZOLS RE, IDHE DC, LINEHAN M, JACOB J, OSTCHEGA Y AND YOUNG RC. (1988). A randomized trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumours. J. Clin. Oncol., 6, 1031-1040.
39. PACCAGNELLA A, ORLANDO A, MARCHIORI C, ZORAT PL, CAVANIGLIA G, SILENI VC, JIRILLO A, TOMIO L, FILA G, FEDE A, ENDRIZZI L, BARI M, SAMPOGNARO E, BALLI M, GAVA A, PAPPAGALLO GL AND FIORENTTNO MV. (1994). Phase II trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the gruppo di studio sui tumori della testa e del collo. J. Natl Cancer Inst., 86, 265-272.
40. PARKER RJ, GILL I, TARONE R, VIONNET JA, GRUNBERG S, MUGGIA FM AND REED E. (1991). Platinum-DNA damage in leucocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis, 12, 1253-1258.
41. PLANTING AST, DE BOER M, VAN DER BURG MEL, STOTER G AND VERWEIJ J. (1991). Pilot study of a short course of weekly high dose cisplatin combined with oral etoposide. Eur. J. Cancer, 27 (suppl. 2),1203.
42. PLANTING AST, STOTER G AND VERWEIJ J. (1992). Phase II study of a short course of weekly cisplatin in locally advanced and recurrent squamous cell carcinoma of the head and neck. Proc. Am. Assoc. Cancer Res., 33, 225.
43. PLANTING AST, VAN DER BURG MEL, DE BOER-DENNERT M, STOTER G AND VERWEIJ J, (1993a). Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. Br. J. Cancer, 68, 789-792.
44. PLANTING AST, GOEY S, DE BOER-DENNERT M, VECHT CH, STOTER G AND VERWEIJ J. (1993b). Phase II study of a short course of weekly cisplatin combined with oral etoposide in pleural mesothelioma. Eur. J. Cancer, 29A, S184.
45. PLANTING AST, SCHELLENS JHM, GOEY SH, VAN DER BURG MEL, DE BOER-DENNERT M, STOTER G AND VERWEIJ J. (1994). Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann. Oncol., 5, 373-374.
46. POIRIER MC, REED E, LITTERST CL, KATZ D AND GUPTA-BURT G. (1992). Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res., 52, 149-153.
47. POIRIER MC, REED E, SHAMKHANI H, TARONE RE AND GUPTABURT S. (1993). Platinum drug-DNA interactions in human tissue measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environm. Health Persp., 99, 149-154.
48. REECE PHA, STAFFORD I, RUSSELL J, KHAN M AND FILL PG. (1987). Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J. Clin. Oncol., 5, 304-309.
49. REECE PA, STAFFORD I, ABBOTT RL, ANDERSON C, DENHAM J, FREEMAN S, MORRIS RG, GILL PG AND OLWENY CL. (1989). Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations. J. Clin. Oncol., 7, P270-275.
50. REED E, YUSPA SH, ZWELLING LA, OZOLS RF AND POIRIER MC. (1986). Quantitation of cis-diamminedichloroplatinum II (cis-platin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J. Clin. Invest., 77, 545-550.
51. REED E, OZOLS RF, TARONE R, YUSPA SH AND POIRIER MC. (1987). Platinum-DNA adducts in leucocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl Acad. Sci. USA, 84, 5024-5028.
52. REED E, OZOLS RF, TARONE R, YUSPA SH AND POIRIER MC. (1988a). The measurements of cisDDP-DNA adduct levels in testicular cancer patients. Carcinogenesis, 9, 1909-1911.
53. REED E, SAUERHOFF S AND POIRIER MC. (1988b). Quantitation of platinum-DNA binding after therapeutic levels of drug exposure - a novel use of graphite furnace spectrometry. Atomic Spectroscopy, 9, 93-95.
54. REED E, OSTCHEGA Y, STEINBERG SM, YUSPA SH, YOUNG RC, OZOLS RF AND POIRIER MC. (1990). Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res., 50, 2256-2260.
55. REED E, PARKER RJ, GILL I, BICHER A, DABHOLKAR M, VIONNET JA, BOSTICK-BRUTON F, TARONE R AND MUGGIA FM. (1993). Platinum-DNA adduct in leucocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res., 53, 3694-3699.
56. ROELOFS RI, HRUSHESKY W, ROGIN J AND ROSENBERG L (1984). Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology, 34, 934-938.
57. ROTH JA, FOSSELLA F, KOMAKI R, RYAN B, PUTNAM JB, LEE JS, DHINGRA H, DECARO L, CHASEN M, MCGAVRAN M, ATKINSON EN AND HONG WK. (1994). A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl Cancer Inst., 86, 673-680.
58. SAMSON MK, RIVKIN SE, JONES SE, COSTANZI JJ, LOBUGLIO AF, STEPHENS RL, GEHAN EA AND CUMMINGS AD. (1984). Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. Cancer, 53, 1029-1035.
59. SHEINER LB AND BEAL SL. (1985). Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J. Pharmacokinet. Biopharmaceut., 13, 185-210.
60. SIEGAL T AND HAIM N. (1990). Cisplatin-induced peripheral neuropathy. Cancer, 66, 1117-1123.
61. SLOTMAN GJ, DOOLITTLE CHH AND GLICKSMAN AS (1992). Preoperative combined chemotherapy and radiation therapy plus radical surgery in advanced head and neck cancer. Cancer, 69, 2736-2743.
62. STOTER G, SPLINTER TAW, CHILD JA, FOSSA SD, DENIS L, VAN OOSTEROM AT, DE PAUW M AND SYLVESTER R. (1987). Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J. Urol., 137, 663-667.
63. STOTER G, LOEHRER PJ AND LEVI J. (1996). Management of non-seminomatous germ cell tumours stage II and good risk stage III and IV. In Principles and Practice of Genitourinary Oncology. Raghavan D, Scher HJ, Leibel SA (eds) JB Lippincott, In press.
64. WORLD HEALTH ORGANIZATION. (1979). Handbook for Reporting Results of Cancer Treatment. World Health Organization: Geneva.